{"id":"W4412522153","doi":"10.1016/s0140-6736(25)00684-1","title":"Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Arena Pharmaceuticals","keywords":"Enzalutamide; Medicine; Prostate cancer; Placebo; Clinical endpoint; Internal medicine; Oncology; Cohort; Androgen deprivation therapy; Cancer; Clinical trial; Androgen receptor; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001703166,0.0002834471,0.00111873,0.00007560394,0.0002249734,0.0001245317,0.0003101724,0.00004951738,0.0000648259],"category_scores_gemma":[0.0003922417,0.0001250174,0.0001264904,0.0003347429,0.0002244013,0.00009475753,0.00005691593,0.0004825154,0.000007573344],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003461335,"about_ca_system_score_gemma":0.001355325,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004932936,"about_ca_topic_score_gemma":0.003421547,"domain_scores_codex":[0.9973499,0.0005361847,0.0005990262,0.0004152821,0.0005527745,0.0005468896],"domain_scores_gemma":[0.9973822,0.001574639,0.0002046842,0.0006484922,0.0001077326,0.00008226137],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9852803,0.0002547735,0.000345628,0.00004601902,0.0008336311,0.0001812731,0.001471487,0.0004548427,0.001694562,0.0002055067,0.008287641,0.0009443111],"study_design_scores_gemma":[0.9894941,0.0007464285,0.001497295,0.0003583553,0.0005707728,0.00000360584,0.0006103722,0.002319705,0.001106549,0.0005299465,0.002613037,0.0001497978],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9461154,0.002757175,0.00002333213,0.03167452,0.0002328203,0.009225825,0.001051577,0.00005233744,0.008866973],"genre_scores_gemma":[0.9850864,0.0009621636,0.0001033614,0.000475511,0.0006173246,0.002158353,0.0003444887,0.00002464979,0.01022777],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03897093,"threshold_uncertainty_score":0.7457157,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05745369416498963,"score_gpt":0.3570725287255095,"score_spread":0.2996188345605199,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}